Company / Shareholders' Equity
PTC Therapeutics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$205.3M
FY2025
5-year range
-$1.1B / $594.3M
FY2021-FY2025
Trend
+81.3%
vs FY2024
Sector context
#204 of 213
Health Care
What the data says
PTC Therapeutics, Inc. reports negative total equity of -$205M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$205M in FY2025.
Improved from -$819M to -$205M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 213This company -$205.3M Sector average $2.5B
▼
-108.1% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity increased 81.3% year-over-year.
- Ranks #204 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
- Lowest shareholders' equity in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$205.3M | +81.3% |
| FY2024 | -$1.1B | -34.1% |
| FY2023 | -$818.6M | -269.8% |
| FY2022 | $482.0M | -18.9% |
| FY2021 | $594.3M | +69.5% |
| FY2020 | $350.7M | -41.0% |
| FY2019 | $594.3M | +69.5% |
| FY2018 | $350.7M | +124.2% |
| FY2017 | $156.4M | +30.8% |
| FY2016 | $119.6M | -47.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026